NASDAQ · PRPO
Healthcare · Medical - Diagnostics & Research
$23.52
Down-$0.27 (-1.15%)
Updated Oct 8, 2026, 5:35 PM
SID Score
3.4/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · PRPO
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 7, 2026
PRPO closed at $23.52 after 21 trading sessions, down 8.13% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 7, 2026 | $22.95 | $24.03 | $22.935 | $23.52 | 66.44K |
| Oct 6, 2026 | $24.00 | $24.2722 | $23.30 | $23.45 | 18.16K |
| Oct 5, 2026 | $23.105 | $24.12 | $22.90 | $24.00 | 43.47K |
| Oct 2, 2026 | $22.96 | $23.95 | $22.875 | $23.13 | 22.7K |
| Oct 1, 2026 | $23.79 | $23.83 | $22.45 | $22.73 | 13.86K |
| Sep 30, 2026 | $23.72 | $24.2295 | $23.63 | $23.68 | 74.24K |
| Sep 29, 2026 | $23.705 | $23.75 | $22.90 | $23.58 | 63.08K |
| Sep 28, 2026 | $23.47 | $24.36 | $23.26 | $24.11 | 72.4K |
| Sep 25, 2026 | $24.33 | $24.62 | $23.45 | $23.65 | 52.31K |
| Sep 24, 2026 | $23.87 | $24.72 | $23.225 | $24.47 | 58.2K |
| Sep 23, 2026 | $26.22 | $26.31 | $23.58 | $23.84 | 39.74K |
| Sep 22, 2026 | $26.39 | $27.035 | $26.11 | $26.265 | 80.49K |
| Sep 21, 2026 | $26.50 | $26.80 | $26.00 | $26.79 | 138.39K |
| Sep 18, 2026 | $26.38 | $26.4825 | $25.74 | $26.46 | 192.26K |
| Sep 17, 2026 | $26.9795 | $26.9795 | $26.09 | $26.44 | 406.72K |
| Sep 16, 2026 | $27.175 | $27.19 | $25.72 | $26.66 | 39.09K |
| Sep 15, 2026 | $27.23 | $27.71 | $26.53 | $27.16 | 111K |
| Sep 14, 2026 | $27.20 | $27.72 | $26.90 | $27.23 | 62.64K |
| Sep 11, 2026 | $27.03 | $28.00 | $26.25 | $27.32 | 89.11K |
| Sep 10, 2026 | $25.21 | $27.405 | $25.21 | $26.91 | 236.33K |
| Sep 9, 2026 | $27.10 | $27.10 | $25.495 | $25.60 | 132.82K |
The latest Smart Investors Daily articles mentioning PRPO.
Company
Market Activity
Research & News
PRPO research
Company profile and research snapshot.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 22, 2019 | Maxim Group | Buy | — |
No generated briefing is available yet.
Yahoo · Sep 22, 2026
Precipio and Fulgent Genetics differ in business scope, valuation and growth drivers, but which cancer diagnostics stock looks more compelling now? Let's dive in.
Benzinga · Sep 18, 2026
Precipio (NASDAQ:PRPO) held its second-quarter earnings conference call on Monday. Below is the complete transcript from the call. This content is powered by Benzinga APIs. For comprehensive financial data and
Yahoo · Sep 11, 2026
Goldman Sachs, RTX and Abbott lead Zacks' latest research, with growth drivers balanced by costs, supply-chain and market risks.
SeekingAlpha · Aug 17, 2026
Precipio, Inc. (PRPO) Q2 2026 Earnings Call August 17, 2026 5:00 PM EDTCompany ParticipantsIlan Danieli - Founder, President, CEO & DirectorConference...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning PRPO.
No results
No recent SID articles mention PRPO.
